Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Tiletamine, Zolazepam

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Injectable Solution Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 9, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Apr 11, 2026, 10:01 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Tiletamine, Zolazepam

Tiletamine, Zolazepam

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Injectable Solution Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Tiletamine, Zolazepam

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation. Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Species commonly shown: Both, Dog, Restricted During Pregnancy, Cat, Restricted During Pregnancy.

Generic name
Tiletamine, Zolazepam
Brand names
Telazol®, Tzed™, ZOLETIL®, Tzed
Manufacturer
Multiple FDA labelers
Species
Both, Dog, Cat
Dosage forms
Injectable Solution
Prescription
Prescription required
Completeness
100%
Validation
Needs review
Brand names
Telazol® Tzed™ ZOLETIL® Tzed Telazol
Dosage forms
Injectable Solution

Indications / Uses

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation. Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

Side Effects

Top reported reactions (openFDA): Acidosis, Anaphylaxis, Ascites, Collapse (see also Cardio-vascular and Systemic disorders), Death by euthanasia, Decreased blood urea nitrogen (BUN) or creatinine.

FAQ

Both, Dog, Restricted During Pregnancy, Cat, Restricted During Pregnancy, Dog, Cat

Yes. Roxee shows this as prescription-only.

Injectable Solution

Related Conditions

Abscesses (cat bite abscess)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Not for use in dogs with pancreatic disease
  • Not for use in dogs with severe cardiac or pulmonary dysfunction
  • Not for use in pregnant bitches at any stage of pregnancy
  • Not for use for Cesarean sections
  • The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function
  • Not for use in cats with pancreatic disease
  • Not for use in cats with severe cardiac or pulmonary dysfunction
  • Not for use in pregnant queens at any stage of pregnancy
  • Not recommended for use in cats suffering from renal insufficiency
  • The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function
  • Thrombocytopenia (1 reports)
  • Tachycardia (1 reports)
  • Seizure NOS (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Tiletamine, Zolazepam; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case FRA-USFDACVM-2017-FR-000010
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 20 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case FRA-USFDACVM-2017-FR-000010
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case FRA-USFDACVM-2017-FR-000010
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Thrombocytopenia (1 reports), Tachycardia (1 reports), Seizure NOS (1 reports), Reduced globulins (1 reports), Pyuria (1 reports)

Body systems represented Signal grouping

Neurologic (1), Effectiveness (1), Other (30)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (29 reports), Cat (3 reports)

Breed metadata in reports Metadata only

Cat (unknown) (2), Dog (unknown) (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Tiletamine, Zolazepam fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Not for use in dogs with pancreatic disease, Not for use in dogs with severe cardiac or pulmonary dysfunction, Not for use in pregnant bitches at any stage of pregnancy, Not for use for Cesarean sections, The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Tiletamine, Zolazepam brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case FRA-USFDACVM-2017-FR-000010 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. FOI · document · documents
  8. SPL · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 22, 2026, 10:06 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Not for use in dogs with pancreatic disease
  • Not for use in dogs with severe cardiac or pulmonary dysfunction
  • Not for use in pregnant bitches at any stage of pregnancy
  • Not for use for Cesarean sections
  • The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function

Most reported reactions:

  • Thrombocytopenia (1 reports)
  • Tachycardia (1 reports)
  • Seizure NOS (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat, Dog
Indication / use
For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.
Form / route / dose
Form: Injectable Solution
Route: Intramuscular, Intravenous
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug t…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Injectable Solution
Identifiers:
ANADA: 200557 ANADA: 200618 NADA: 106111 NDC Package: 17033-010-05 NDC Package: 54771-9050-1 NDC Product: 17033 NDC Product: 54771
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
3
Matching reports
1
Active filters
1
Selected filters
Reaction: Decreased body temperature Clear
Reset
Drill into common report signals
Lack of efficacy - NOS (2) Death (1) Decreased body temperature (1) Effectiveness (2) Other (1)
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-074297

Received 2025-12-11 · MSK · MSK

Serious
Species
Cat
Breed
Cat (unknown)
Sex
Unknown Unknown
Region
USA
Reactions
DeathDecreased body temperature
Body systems
Other
Outcomes
Died

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
20
Species represented
2
Grouped by Body System
Neurologic (1) · Seizure NOS Effectiveness (1) · Lack of efficacy - NOS Other (30) · Thrombocytopenia, Tachycardia, Shaking
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Dog 1
Other 1 Dog 1
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (29) Cat (3)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Neurologic Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Effectiveness Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

ZOLETIL® SPL · SPL Tzed™ SPL · SPL Telazol® SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

5

FOI

5

ZOLETIL®

SPL · SPL

Open original
FDA Structured Product Label

ZOLETIL®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Virbac AH, Inc.
ANADA
200-618
Status
RX
Form
Injectable Solution
Route
Intramuscular, Intravenous
Species
Dog • Cat
Composition / specifications
The addition of 5 mL sterile water for injection, USP results in each one mL containing 50 mg tiletamine and 50 mg zolazepam.

Dogs

Indication

For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Dosage

In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg).The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function.

Indication

Indicated for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

Intravenous (IV) (dogs only) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:

In dogs, for induction of anesthesia, administer at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Zoletil for Injection may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Cats

Indication

For restraint or for anesthesia combined with muscle relaxation.

Dosage

In healthy cats, an initial dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario-hysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

Tzed™

SPL · SPL

Open original
FDA Structured Product Label

Tzed™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
ANADA
200-557
Status
RX
Form
Injectable Solution
Route
Intramuscular, Intravenous
Species
Dog • Cat

Dogs

Indication

Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Dosage
The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam.an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).
Indication

For induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

Administer Tzed intravenously at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Tzed should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Tzed may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Cats

Indication

Tzed™ is indicated in cats for restraint or for anesthesia combined with muscle relaxation

Dosage
The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam an initial dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).

Telazol®

SPL · SPL

Open original
FDA Structured Product Label

Telazol®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
106-111
Status
RX
Form
Injectable Solution
Route
Intravenous
Species
Dog • Cat
Composition / specifications
Tiletamine hydrochloride and zolazepam hydrochloride for injection when reconstituted with sterile distilled water provides tiletamine hydrochloride and zolazepam hydrochloride equivalent to 50 milligrams of tiletamine base and 50 milligrams of zolazepam base per milliliter of solution.

Dogs

Indication

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

DogsIntramuscular (IM) For Restraint and MinorProcedures of Short Duration Requiring Mild toModerate Analgesia:In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) TELAZOL is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of TELAZOL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). (See Animal Safety.) Results from TELAZOL anesthesia in dogs will be more satisfactory if theprocedures are completed within one hour and if the procedures can be completed following single dose administration. In order to maintain at least a 2X margin of safety in dogs, the use of this product is limited to procedures that call for low doses (see Indications). Studies show that there is variation in response to different dosages of TELAZOL and that low doses do not give adequate levels of anesthesia, and in some instances do not give adequate analgesia, for extensive procedures.Intravenous (IV) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:In dogs, for induction of anesthesia, administer TELAZOL intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) body weight to effect. TELAZOL should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional TELAZOL may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.

Dosage

In healthy cats, an initial TELAZOL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) IM is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario hysterectomy and onychectomy. When supplemental doses of TELAZOL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg). (See Animal Safety.)

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Telazol SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Telazol. Use the source link for the full official labeling record.

Tzed SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Tzed. Use the source link for the full official labeling record.

FOI Summary sA 200-618 Approved August 16, 2021.pdf

FOI · FOI

Open original

FOI Summary oA-200-618 Approved June 23, 2017.pdf

FOI · FOI

Open original

FOI Summary sA 200-557 Approved November 25, 2020 .pdf

FOI · FOI

Open original

UCM443074.pdf

FOI · FOI

Open original

FOI Summary sN 106-111 Approved November 9, 2017.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Apr 11, 2026, 10:01 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Telazol Tzed
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Injectable Solution • Intramuscular, Intravenous
Applications: ANADA 200-618 • ANADA 200-557 • NADA 106-111
NDC: Packages 17033-010-05 54771-9050-1 • Products 17033 54771
Documents: 5 (FOI: 5) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 1 • Cat 3 • View
Case summaries: 3 (showing 3) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Abscesses (cat bite abscess)
Linked using: Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function. (Contraindication, High)
Top reaction signals
Thrombocytopenia (1) Tachycardia (1) Seizure NOS (1) Reduced globulins (1) Pyuria (1) Leucocytosis NOS (1) Hypotension (1) Hypoproteinaemia (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200557 ANADA: 200618 NADA: 106111 NDC Package: 17033-010-05 NDC Package: 54771-9050-1 NDC Product: 17033 NDC Product: 54771
Package NDC Product NDC Form / Route Status
17033-010-05 17033 -
54771-9050-1 54771 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 119 Clinical 8 Manufacturer 0 Marketing 0
Current Field Facts
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Acidosis, Anaphylaxis, Ascites, Collapse (see also Cardio-vascular and Systemic disorders), Death by euthanasia, Decreased bl… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-22)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-22)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-22)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-21)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-20)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-13)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-12)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-12)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-11)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-11)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-10)
  • indications: Tiletamine-Zolazepam is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of sho… (Official, 2026-06-09)
Recent Revisions
  • side_effects updated 2026-04-22 10:06 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:06 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:06 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-21 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-21 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-21 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-21 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-21 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-21 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-20 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-20 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-20 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-20 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-20 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-20 10:08 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-19 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-19 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-19 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-19 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-19 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
ZOLETIL®
RX
Tiletamine Hydrochloride Zolazepam Hydrochloride
Injectable Solution • Intramuscular, Intravenous
Label highlights
Official documents
Virbac AH, Inc. ANADA 200-618 Approved Aug 22, 2024
Tzed™
RX
Tiletamine Hydrochloride Zolazepam Hydrochloride
Injectable Solution • Intramuscular, Intravenous
Label highlights
Official documents
Dechra Veterinary Products LLC ANADA 200-557 Approved Nov 30, 2020
Telazol®
RX
Tiletamine Hydrochloride Zolazepam Hydrochloride
Injectable Solution • Intravenous
Label highlights
Official documents
Zoetis Inc. NADA 106-111 Approved Dec 7, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog • Cat
Composition / specifications
The addition of 5 mL sterile water for injection, USP results in each one mL containing 50 mg tiletamine and 50 mg zolazepam.
Dogs
Indication

For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Dosage

In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg).The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function.

Indication

Indicated for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

Intravenous (IV) (dogs only) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:

In dogs, for induction of anesthesia, administer at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Zoletil for Injection may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Limitations
Cats
Indication

For restraint or for anesthesia combined with muscle relaxation.

Dosage

In healthy cats, an initial dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario-hysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Dogs
Indication

Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Dosage
The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam.an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).
Limitations
Indication

For induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

Administer Tzed intravenously at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Tzed should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Tzed may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Limitations
Cats
Indication

Tzed™ is indicated in cats for restraint or for anesthesia combined with muscle relaxation

Dosage
The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam an initial dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).
Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Tiletamine hydrochloride and zolazepam hydrochloride for injection when reconstituted with sterile distilled water provides tiletamine hydrochloride and zolazepam hydrochloride equivalent to 50 milligrams of tiletamine base and 50 milligrams of zolazepam base per milliliter of solution.
Dogs
Indication

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Dosage

DogsIntramuscular (IM) For Restraint and MinorProcedures of Short Duration Requiring Mild toModerate Analgesia:In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) TELAZOL is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of TELAZOL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). (See Animal Safety.) Results from TELAZOL anesthesia in dogs will be more satisfactory if theprocedures are completed within one hour and if the procedures can be completed following single dose administration. In order to maintain at least a 2X margin of safety in dogs, the use of this product is limited to procedures that call for low doses (see Indications). Studies show that there is variation in response to different dosages of TELAZOL and that low doses do not give adequate levels of anesthesia, and in some instances do not give adequate analgesia, for extensive procedures.Intravenous (IV) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:In dogs, for induction of anesthesia, administer TELAZOL intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) body weight to effect. TELAZOL should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional TELAZOL may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats
Indication

TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.

Dosage

In healthy cats, an initial TELAZOL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) IM is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario hysterectomy and onychectomy. When supplemental doses of TELAZOL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg). (See Animal Safety.)

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation. Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Neurologic
Seizure NOS (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other
Thrombocytopenia (1) • Dog Tachycardia (1) • Dog Shaking (1) • Cat Renal tubular disorder (1) • Dog Reduced globulins (1) • Dog
Show more (25)
Pyuria (1) • Dog Polyuria (1) • Dog Polydipsia (1) • Dog Leucocytosis NOS (1) • Dog Hypotension (1) • Dog Hyposthenuria (1) • Dog Hypoproteinaemia (1) • Dog Hypoalbuminaemia (1) • Dog Hyperthermia (1) • Dog High blood pressure (1) • Dog Haematuria (1) • Dog Glucosuria (1) • Dog Elevated temperature (1) • Dog Elevated alanine aminotransferase (1) • Dog Dysphoria (1) • Dog Decreased packed cell volume (1) • Dog Decreased body temperature (1) • Dog Decreased blood urea nitrogen (BUN) or creatinine (1) • Dog Death by euthanasia (1) • Dog Death (1) • Cat Collapse (1) • Dog Ascites (1) • Dog Anaphylaxis (1) • Dog Administration error NOS (1) • Cat Acidosis (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Cat (unknown), Unknown • Drug: MSK, Injection, Intramuscular, Dose: 0.30 mL per dose, Frequency: 1 per day • Reactions: Death, Decreased body temperature • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074297
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Injection
  • Dose: 0.30 mL per dose
  • Frequency: 1 per day
Reactions Reported:
Death Decreased body temperature
Outcomes: Died

Dog, Dog (unknown), Unknown • Drug: MSK, Injection, Intramuscular, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Lack of efficacy - NOS • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071331
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Injection
  • Dose: 1 dose per animal
  • Frequency: 1 per day
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Recovered/Normal

Cat, Cat (unknown), Unknown • Drug: MSK, Injection, Intramuscular, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Lack of efficacy - NOS • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071320
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Injection
  • Dose: 1 dose per animal
  • Frequency: 1 per day
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.